Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GPR6 | P46095 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5829758 | 0.80 | OPRD1 (0.47) | OPRD1OPRM1OPRK1CHRM4 | |
| SCHEMBL5879393 | 0.77 | OPRD1 (0.59) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL5830417 | 0.76 | OPRM1 (0.38) | OPRD1OPRM1OPRK1CHRM4 | |
| SCHEMBL5490000 | 0.75 | OPRD1 (0.62) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5879402 | 0.74 | OPRD1 (0.59) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5879389 | 0.73 | OPRD1 (0.66) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5879308 | 0.73 | OPRD1 (0.54) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5493796 | 0.72 | OPRD1 (0.48) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5829827 | 0.72 | SLC6A2 (0.43) | KCNH2 | |
| SCHEMBL5879387 | 0.71 | OPRD1 (0.59) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064137-B2 | Analgesics; anxiolytic agents; gastrointestinal disorders | ASTRAZENECA AB (SE) | 2006-06-20 | — | — | US | disclosed |
| EP-1395558-B1 | 4-(PHENYL-(PIPERIDIN-4-YL)-AMINO)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2005-12-21 | — | — | EP | disclosed |
| US-20040152731-A1 | 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide derivaties and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152731-A1 | 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide derivaties and their use for the treatment of pain, anxiety or gastrointestinal disorders | HTR2C, OPRK1, OPRL1 | OPRD1 4/4885OPRM1 8/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.